Rene Scheenstra
Overview
Explore the profile of Rene Scheenstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li W, Kotsou T, Hartog H, Scheenstra R, de Meijer V, Stenekes M, et al.
Dig Liver Dis
. 2024 Oct;
57(2):502-511.
PMID: 39379231
Aim: This study aimed to investigate the outcomes and effectiveness of various treatment strategies in patients with hepatic artery stenosis (HAS) after pediatric liver transplantation (pLT). Methods: This is a...
2.
Hartleif S, Hodson J, Lloyd C, Cousin V, Czubkowski P, DAntiga L, et al.
Transplantation
. 2023 May;
107(11):2394-2405.
PMID: 37143195
Background: The histological prevalence of allograft fibrosis in asymptomatic children after liver transplantation (LT) is well documented. However, long-term graft and patient survival remain unclear. This retrospective multicenter study aims...
3.
Lexmond W, de Meijer V, Scheenstra R, Bontemps S, Duiker E, Scholvinck E, et al.
United European Gastroenterol J
. 2022 Jun;
10(8):795-804.
PMID: 35773246
There is increasing global concern of severe acute hepatitis of unknown etiology in young children. In early 2022, our center for liver transplantation in the Netherlands treated five children who...
4.
Fidder S, Bolling M, Diercks G, Pas H, Hooimeijer L, Bungener L, et al.
Pediatr Transplant
. 2021 May;
25(6):e14023.
PMID: 34014017
Background: PNP is a malignancy-associated autoimmune mucocutaneous syndrome due to autoantibodies against plakins, desmogleins, and other components of the epidermis and basement membrane of epithelial tissues. PNP-causing malignancies comprise mainly...
5.
Bos G, Timmer C, Lelieveld O, Scheenstra R, Sauer P, Geertzen J, et al.
Pediatr Transplant
. 2020 Aug;
24(7):e13803.
PMID: 32860738
To determine prospectively gross and fine motor development of children <2 years of age, who undergo LTX. In this prospective study, children aged <2 years who undergo LTX were tested...
6.
Werner M, Adelmeijer J, de Meijer V, de Kleine R, Scheenstra R, Bontemps S, et al.
Thromb Haemost
. 2020 Jul;
120(9):1240-1247.
PMID: 32629499
Background: Pro- and anticoagulant drugs are commonly used in pediatric liver transplantation to prevent and treat thrombotic and bleeding complications. However, the combination of baseline hemostatic changes in children with...
7.
Werner M, de Kleine R, de Boer M, de Meijer V, Scheenstra R, Verkade H, et al.
Thromb Haemost
. 2020 Jan;
120(4):627-637.
PMID: 31995833
Background: Hepatic artery thrombosis (HAT) and portal vein thrombosis (PVT) are serious causes of morbidity and mortality after pediatric liver transplantation. To reduce thrombotic complications, routine antithrombotic therapy consisting of...
8.
Werner M, de Meijer V, Adelmeijer J, de Kleine R, Scheenstra R, Bontemps S, et al.
Am J Transplant
. 2019 Dec;
20(5):1384-1392.
PMID: 31841272
In adults with end-stage liver disease concurrent changes in pro- and antihemostatic pathways result in a rebalanced hemostasis. Children though, have a developing hemostatic system, different disease etiologies, and increased...
9.
Haisma S, Verkade H, Scheenstra R, van der Doef H, Bodewes F, van Rheenen P
J Pediatr Gastroenterol Nutr
. 2019 Aug;
69(4):466-473.
PMID: 31365486
Objectives: Treatment targets in inflammatory bowel disease (IBD) move away from controlling symptoms towards complete recovery of the intestinal mucosa. Currently, the most frequently used noninvasive surrogate marker of mucosal...
10.
Bos G, Lelieveld O, Scheenstra R, Sauer P, Geertzen J, Dijkstra P
Pediatr Transplant
. 2019 Jun;
23(5):e13465.
PMID: 31169339
To determine physical activity (PA), aerobic fitness, muscle strength, health-related quality of life (HRQOL), fatigue, and participation in children after liver transplantation. Children, 6-12 years, at least one year after...